175 related articles for article (PubMed ID: 24339902)
1. The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
Powers GL; Rajbhandari P; Solodin NM; Bickford B; Alarid ET
PLoS One; 2013; 8(12):e81110. PubMed ID: 24339902
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA
Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Kinyamu HK; Bennett BD; Bushel PR; Archer TK
J Biol Chem; 2020 Jan; 295(5):1271-1287. PubMed ID: 31806706
[TBL] [Abstract][Full Text] [Related]
7. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
8. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
10. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters.
Kininis M; Chen BS; Diehl AG; Isaacs GD; Zhang T; Siepel AC; Clark AG; Kraus WL
Mol Cell Biol; 2007 Jul; 27(14):5090-104. PubMed ID: 17515612
[TBL] [Abstract][Full Text] [Related]
11. Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha.
Gao Y; Chen L; Han Y; Wu F; Yang WS; Zhang Z; Huo T; Zhu Y; Yu C; Kim H; Lee M; Tang Z; Phillips K; He B; Jung SY; Song Y; Zhu B; Xu RM; Feng Q
Commun Biol; 2020 Apr; 3(1):165. PubMed ID: 32265480
[TBL] [Abstract][Full Text] [Related]
12. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Taylor MD; Liu Y; Nagji AS; Theodosakis N; Jones DR
J Thorac Cardiovasc Surg; 2010 May; 139(5):1224-32, 1232.e1. PubMed ID: 20412959
[TBL] [Abstract][Full Text] [Related]
13. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
15. The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer-promoter interactions.
Tong Z; Liu Y; Yu X; Martinez JD; Xu J
J Biol Chem; 2019 Dec; 294(51):19667-19682. PubMed ID: 31744881
[TBL] [Abstract][Full Text] [Related]
16. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Cooper C; Liu GY; Niu YL; Santos S; Murphy LC; Watson PH
Clin Cancer Res; 2004 Dec; 10(24):8720-7. PubMed ID: 15623657
[TBL] [Abstract][Full Text] [Related]
17. Dynamic assembly and activation of estrogen receptor α enhancers through coregulator switching.
Murakami S; Nagari A; Kraus WL
Genes Dev; 2017 Aug; 31(15):1535-1548. PubMed ID: 28887413
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.
Goffin L; Seguin-Estévez Q; Alvarez M; Reith W; Chizzolini C
Arthritis Res Ther; 2010; 12(2):R73. PubMed ID: 20429888
[TBL] [Abstract][Full Text] [Related]
20. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
